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Abstract: The clinical expectations how pathologists should submit lung cancer diagnosis have changed 
dramatically. Until mid 90-ties a clear separation between small cell lung carcinoma (SCLC) and non-
small cell lung carcinoma (NSCLC) was mostly sufficient. With the invention of antiangiogenic treatment a 
differentiation between squamous and non-squamous NSCLC was requested. When epidermal growth factor 
receptor (EGFR) mutation was detected in patients with pulmonary adenocarcinomas and subsequent specific 
treatment with tyrosine kinase inhibitors (TKIs) was invented, sub-classification of NSCLC and molecular 
analysis of the tumor tissue for mutations was asked for. Pathologists no longer submit just a diagnosis, but 
instead are involved in a multidisciplinary team for lung cancer patient management. After EGFR several 
other driver genes such as echinoderm microtubule associated protein like 4-AL-Kinase 1 (EML4-ALK1), 
c-ros oncogene 1 , receptor tyrosine kinase (ROS1), discoidin domain receptor tyrosine kinase 2 (DDR2), 
fibroblast growth factor receptor 1 (FGFR1) were discovered, and more to come. Due to new developments in 
bronchology (EUS, EBUS) the amount of tissue submitted for diagnosis and molecular analysis is decreasing, 
however, the genes to be analyzed are increasing. Many of these driver gene aberrations are inversions or 
translocations and thus require FISH analysis. Each of these analyses requires a certain amount of tumor cells 
or one to two tissue sections from an already limited amount of tissues or cells. In this respect new genetic test 
systems have been introduced such as next generation sequencing, which enables not only to detect multiple 
mutations in different genes, but also amplifications and fusion genes. As soon as these methods have been 
validated for routine molecular analysis this will enable the analysis of multiple genetic changes simultaneously. 
In this review we will focus on genetic aberrations in NSCLC, resistance to new target therapies, and also to 
methodological requirements for a meaningful evaluation of lung cancer tissue and cells.
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Introduction
Within the last decade many important discoveries 
were made in the regulation of growth, differentiation, 
apoptosis, and metastasis of lung cancers. These findings 
have dramatically changed the view of the oncology 
community about the importance of the classification of 
lung carcinomas. With the findings of different responses 
for cisplatin treatment in adenocarcinomas versus squamous 
cell carcinomas (SCCs) this simple clinical lung carcinoma 
classification schema small cell lung carcinoma (SCLC) 
versus non-small cell lung carcinoma (NSCLC) was 
abolished. In addition, results of recent research show even 
the category of adenocarcinoma is in fact a heterogeneous 
group of different tumors with a broad spectrum of 
molecular changes. The chance of targeting at least some of 
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the mutations by currently available treatment thus requires 
much more precise classification of lung tumors based not 
solely on morphology, but including even detection of 
various molecular predictive markers.
Therapy relevant molecular changes in 
pulmonary carcinomas
NSCLC and angiogenesis
In the last decade humanized antibodies have been developed 
to interfere with the neoangiogenesis in primary as well as 
metastatic carcinomas (1,2). However, anti-angiogenetic 
drugs can cause severe bleeding, especially when administered 
in patients with centrally located NSCLC. However, it is still 
not clear, if the reported bleeding episodes in these patients 
are due to the squamous histology or more logically to the 
central located tumors, which are usually supported by 
arteries and veins arising from large branches. In addition, 
it was reported that cavitation within the tumor is prone 
to hemorrhage, again something more common in central 
tumors located close to large blood vessels (3). The erroneous 
perception of oncologists about SCCs most probably is due 
to the fact that SCCs arise predominantly in central bronchi.
Angiogenesis, better neoangiogenesis is a process by 
which primary tumors get access to nutrients and oxygen 
and is characterized by the sprouting of endothelial cells 
from the preexisting vessels (in contrast to vasculogenesis, 
which is the process of growth of the vessels de novo—
e.g., during embryonic development). The process of 
neoangiogenesis is still not fully understood. Under normal 
circumstances endothelial cells are virtually quiescent, 
therefore a crucial requirement for neoangiogenesis is their 
stimulation to proliferation by angiogenic factors, such as 
vascular endothelial growth factors (VEGFs). In some cases 
are these factors produced by the tumor cells themselves, in 
other cases are these growth factors produced by elements 
of the immune system, such as macrophages present in the 
tumor microenvironment (4). However, once new blood 
vessels (capillaries, small arteries, veins) are formed, this 
provides advantage for the tumor cells over their normal 
neighbor cells in getting better oxygen and nutrient supply. 
Nutrients and oxygen are not the only important factor for 
rapid growth, also purine and pyrimidine bases are essential 
for a dividing tumor cell (5,6). Increased angiogenesis 
itself in invasive adenocarcinomas has a negative impact on 
survival and progression of disease in these patients (7).
Angiogenesis is essential for the primary tumor as well 
as for metastasis. The secretion of VEGFs facilitates most 
often neoangiogenesis. Tumor blood vessels are immature, 
with incomplete basement membrane, fragile, and are 
therefore prone to rupture. Using antibodies against VEGF 
(bevacizumab) the angiogenesis can be inhibited and 
regression of the tumor is induced. However, in some cases, 
mostly in centrally located tumors can this therapy result in 
severe hemorrhage.
New developments are focusing on the inhibition of the 
VEGF receptors (VEGFRs) and also on the role of hypoxia 
inducible factor (HIF) and hypoxia in tumor development 
and metastasis. In several studies the importance of VEGF 
and VEGFR axis was stated for vascular invasion and 
metastasis, mainly involving VEGF-C and VEGFR3 (7-10). 
Studies aiming to target this axis showed positive results 
in experimental settings (11-13). Bringing these targeted 
therapies into clinical trials is still in its infancy (14). 
A major problem in targeting VEGF-VEGFR is the 
fact that its regulation is under the major influence of 
the hypoxia pathway. Hypoxia is an important factor in 
invasion and angioinvasion, and HIF1-signaling will result 
in the upregulation of VEGF (15,16). So the hypoxia 
pathway might constantly overrule a blockade of VEGF-
VEGFR unless also HIF1 production is inhibited (17). 
In addition, several other independent pathways regulate 
the angiogenesis and thus blocking of just one of them 
is sooner or later bypassed by another one resulting in 
resistance and failure of the anti-angiogenic treatment.
NSCLC and cisplatin drugs, the effect of anti-apoptotic 
signaling
In a large multi-institutional study the effect of cisplatin 
chemotherapy was investigated. High expression of 
deoxyribonucleic acid (DNA) repair enzymes, especially 
excision repair cross complementation group 1 (ERCC1) 
was found to be responsible for failure of cisplatin 
chemotherapy and this expression correlated predominantly 
with squamous cell histology (18). ERCC1 is part of the 
excision repair machinery involved in the repair of damaged 
DNA. In NSCLC showing a high expression of this 
enzyme, the action of cisplatin-based chemotherapeutics is 
inefficient, most probably because DNA damage induced 
by the drug is immediately repaired. In a subsequent report 
the usefulness of ERCC1 immunohistochemistry failed, 
probably because the antibody clone did not pick up the 
relevant splice variant of ERCC1. Therefore the authors 
suggested using messenger ribonucleic acid (mRNA) 
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quantification instead.
Thymidilate synthase (TS) blocker
Pemetrexed is an inhibitor of TS less for the other enzymes 
in the thymidine cycle. Thymidine uptake is essential 
for rapidly dividing carcinoma cells. In tumors with low 
expression of TS pemetrexed can block the enzyme resulting 
in growth inhibition. TS expression most often is low in 
adenocarcinomas, but is highly expressed in many SCCs. 
Thus pemetrexed is efficient in most adenocarcinomas and 
not in SCCs (19). However, the action of pemetrexed is 
still not entirely clear: thymidylate metabolism does not 
only rely on enzymes of the thymidylate cycle, but also 
needs active and passive uptake mechanisms; and thymidine 
uptake might also be influenced by pemetrexed (20).
Receptor tyrosine kinases (RTKs) in lung carcinomas
RTKs are membrane-bound protein receptor composed 
of an extracellular receptor domain, a transmembrane 
spanning portion, and an internal (intracellular) domain, 
which at its C-terminal end contains the kinase domain. 
The external receptor domain has a specific configuration 
for the binding of growth factors. Such stimulation results 
in dimerization of the receptor, where two molecules 
form either homo- or heterodimer. This specific binding 
changes the configuration of the whole receptor and leads 
to the phosphorylation and activation of the kinase domain. 
There are two ways of activation of RTKs in lung cancer: 
overproduction of ligands either by the tumor cell or by 
cells within the microenvironment, such as macrophages; 
or activation by a mutation of the receptor gene, most 
often within the kinase domain. The receptor kinase 
itself can act also in two different ways: one is transfer of 
phosphorylation to transfer molecules (21,22), like GAB1 
or Grb2; or the kinase splits into fragments, where one 
activated protein fragment translocates into the nucleus and 
binds to specific DNA elements and induces transcription 
of downstream proteins (23). In lung cancer RTKs can be 
constantly activated by different mechanisms: amplification 
of the RTK gene, mutations of the RTK gene, gene 
rearrangements (translocation/inversion) with constant 
activation or inactivation of regulatory proteins. Another 
mechanism is downregulation of regulatory proteins by 
microRNAs (miRNAs), so a tumor suppressor or a negative 
feedback protein is not synthesized because of mRNA 
inactivation by miRNA (24-29).
Adenocarcinomas
Adenocarcinomas in highly industrialized countries are the 
most common lung carcinoma, representing up to 40% 
of all lung carcinomas. In addition what was previously 
regarded as a single entity has become a huge diversity 
of carcinomas. Adenocarcinomas in never-smokers most 
probably represent a separate entity with different etiology, 
pathogenesis, and gene signatures and a slower progression 
rate compared to adenocarcinomas in smokers. Also recent 
studies of gene signatures have contributed to a more 
heterogeneous picture of these neoplasms. Morphologically 
adenocarcinomas can show a variety of patterns, which in 
part correlate with gene signatures, although our knowledge 
in this respect is still in its infancy.
Adenocarcinoma is defined by the formation of papillary, 
micropapillary, cribriform, acinar, and solid structures, the 
latter with mucin synthesis-mucin-containing vacuoles in at 
least 10% of the tumor cells. Adenocarcinomas can be either 
mucinous or non-mucinous. Both will show the above-
mentioned patterns. Some rare variants are fetal, colloid, 
and enteric adenocarcinomas. Most often a mixed pattern is 
seen with a predominance of at least one component.
Tumor cells in adenocarcinomas can show differentiations 
along well-known cell types as Clara cells, pneumocytes type 
II, columnar cells, and goblet cells. Due to the importance of 
targeted therapy the exact classification of adenocarcinomas 
and their differentiation from other NSCLC has become a 
major task in pulmonary pathology. Differentiation factors 
are used to prove the nature of the carcinoma especially in 
poorly differentiated tumors. A variety of useful markers 
have been tested, the most important ones are thyroid 
transcription factor-1 (TTF1), cytokeratin 7 and Napsin A.
Epidermal growth factor receptor (EGFR)
In 2004, an EGFR mutation was detected in a patient with 
lung adenocarcinoma and responded to tyrosine kinase 
inhibitor (TKI) treatment—a new era of targeted therapy in 
NSCLC has started (30,31).
Mutation of EGFR has been detected in a small percentage 
of lung cancer patients in the Caucasian population. These 
are activating mutations found in exons 18, 19, 20, and 21 
of the EGFR gene (kinase domain) (32). Mutations are 
most often found in never smokers, females, and in patients 
with adenocarcinoma histology. Mutations change the 
configuration of the kinase, which does not need anymore 
the ligand-based activation from the receptor domain. The 
receptor stays in an activated stage and constantly signals 
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downstream. Proliferation of neoplastic cells in carcinomas 
with this activating mutation can be inhibited by small 
receptor TKIs such as gefitinib, erlotinib, and afatinib. These 
TKIs bind either reversibly or irreversibly into the adenosine 
triphosphate (ATP) pocket of the mutated EGFR kinase 
domain and thus inhibit phosphor-transfer to downstream 
molecules, thus blocking the signaling cascade (33). 
The most common mutations are deletions within exon 19 
with a variation of 9-18 nucleotides, and a point mutation at 
exon 21 (L858R). Other less common mutations are point 
mutations in exon 18, and insertions in exon 20.
However, mainly within exon 20 there are also resistance 
mutations, the best known is T790M. This type of mutation 
inhibits or reverses the binding of the TKIs gefitinib 
and erlotinib and prevents the receptor blockade. The 
occurrence of T790M is most frequently associated with 
previous TKI treatment. This mutation can be present 
in the tumor cells already before the treatment initiation 
and becomes detectable as a result of clonal selection 
(overgrowth of resistant cell population) or it originates de 
novo. The irreversible TKI afatinib might overrule some 
of these resistance mutations, but more data are needed to 
prove this (34).
Treatment response with TKIs is best in exon19 
deletions, followed by exon21 point mutation. Mutations 
within exon 18 and 20 are less responsive (35).
For targeted therapy with TKIs tissue samples of 
NSCLC have to be analyzed for these mutations. Within 
the different subtypes of adenocarcinomas some will 
show a higher percentage of EGFR mutations, whereas 
others not. In Caucasian population adenocarcinomas 
with acinar or papillary pattern are mutated in up to 
27%, whereas mucinous adenocarcinomas are constantly 
negative for EGFR mutations (and show KRAS mutation 
instead). Carcinomas with biphasic morphology such 
as adenosquamous carcinomas and mixed small cell and 
adenocarcinomas can show mutations but usually in a very 
small percentage of cases.
Another therapy approach was tested with humanized 
monoclonal antibodies for EGF. By competitive binding to 
the receptor, this antibody replaces EGF and thus inhibits 
transactivation of the kinase. This type of therapy seems 
to be especially promising in EGFR-naïve (wild-type) 
adenocarcinomas and in addition also in SCCs (36,37).
Echinoderm microtubule associated protein like 4-AL-
Kinase 1 (EML4-ALK1) and additional fusion partners 
Inversion of the ALK1 kinase gene and fusion with the 
EML4 gene has been recently shown in patients with 
NSCLC, especially in solid adenocarcinomas with focal 
differentiation into signet ring cells. Subsequently other 
patterns have been associated with this type of gene 
rearrangement, such as micropapillary. Both genes are 
on chromosome 2; the chromosomal break is inversely 
rearranged whereby the kinase domain of ALK and EML4 
are fused together. The ALK kinase thus is under the 
control of EML4, which results in a constant activation of 
the kinase. ALK similarly to EGFR stimulates proliferation 
and inhibits apoptosis. Patients with this inversion respond 
excellently to crizotinib treatment, which is now the second 
example of targeted therapy in NSCLC (38). Proof of 
EML4ALK1 inversion can be done with different methods: 
the most common is FISH where two probes (3' and 5') 
detecting the ALK gene on both sides of the breakpoint 
are used. In the normal situation these probes will detect 
the two portions close together or overlapping within the 
tumor nucleus (resulting in fused FISH signal). In cases of 
rearrangement, the probes will highlight each of the splitted 
portions of the ALK1 gene, so instead of two overlapping 
signals the signals split apart. In the Caucasian population 
EML4ALK1 rearrangement is usually found in 4-6% of 
NSCLC; in adenocarcinomas this might be increased to 8%.
Other genes joining the ALK1 gene in the same way 
can replace the EML4 gene. If kinesin family member 5B 
(KIF5B) joins to ALK1, the overexpression of KIF5B-
ALK (27) in mammalian cells led to the activation of signal 
transducer and activator of transcription 3 (STAT3) and 
protein kinase B and enhanced cell proliferation, migration, 
and invasion (27). Another fusion partner recently described 
is ALK-KLC1 (39). These other ALK1 fusions are rare; the 
incidence is about 1%.
C-ros oncogene 1, receptor tyrosine kinase (ROS1)
ROS1 is another kinase involved as a driver gene in 
adenocarcinomas of the lung (40). Usually the rearrangement 
of ROS1 is evaluated by two FISH probes for the 3'- and 
the 5'- ends. Only few fusion partners have been identified 
so far, CD74, SLC34A2, EZR, and GOPC/FIG (41,42). 
This gene rearrangement has no influence on outcome, 
but similar to ALK1 this is usually a younger population of 
cancer patients (43). The incidence of ROS1 rearrangement 
is in the range of 1%. The function of one of the fusion 
genes EZR-ROS was studied in a mouse model and showed 
that in this experimental setting the fusion gene acted as an 
oncogene inducing multiple tumor nodules in mice (44). 
Most important patients with this type of gene aberrations 
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responded well to the ALK1 inhibitor crizotinib (45-47).
KIF5B and ret proto-oncogene , receptor tyrosine 
kinase (RET) 
KIF5B is one of the fusion partners for either ALK1 
or RET. The KIF5B-RET fusion gene is caused by a 
pericentric inversion of 10p11.22-q11.21. This fusion 
gene overexpresses chimeric RET RTK, which can 
spontaneously induce cellular transformation (48). 
Besides KIF5B, CCDC6, and NCOA4 can form fusion 
genes with RET. Patients with lung adenocarcinomas 
with RET fusion gene have more poorly differentiated 
tumors, are younger, and more often never-smokers. 
Solid adenocarcinomas predominate, tumors are smaller 
but lymph node involvement is higher. The incidence of 
RET fusion is about in 1% of NSCLCs and almost 2% of 
adenocarcinomas (48-50).
Met proto-oncogene, receptor tyrosine kinase (MET)
MET is another RTK bound to cell membranes in NSCLC. 
The ligand for MET is hepatocyte growth factor (HGF), 
originally found in hepatic carcinomas. This receptor came 
into consideration in NSCLC because amplification of 
MET or alternatively upregulation of HGF was identified 
as a mechanism of the resistance in EGFR mutated 
adenocarcinomas treated by TKI (25,51). A search for the 
role of MET in other NSCLC excluding EGFR mutated 
adenocarcinomas showed, that MET amplification was a 
rare event, but upregulation of MET is relatively common: 
approximately 20% of NSCLC including adenocarcinomas 
and SCCs showed high protein expression, but only 2% 
MET amplification (Popper et al. in preparation). Clinical 
studies are in progress to evaluate the possibility to interfere 
with MET signaling using monoclonal antibodies. Other 
studies use small molecule inhibitors for MET. Since MET 
expression is common in EGFR mutated adenocarcinomas 
some studies aim to inhibit both EGFR and MET signaling 
pathways (52). In a phase III trial the combination of EGFR 
TKI and MET inhibition failed, most probably because the 
cut-off levels were not properly set (personal experience and 
Popper et al. in preparation).
Squamous cell carcinomas (SCCs)
SCC is  def ined by a  plate- l ike layering of  cel l s , 
keratinization of at least single cells, intercellular gaps and 
bridges (represented by desmosomes and hemidesmosomes), 
and expression of high molecular weight cytokeratins (CK 
3/5, 13/14). There are some morphologic variants as small 
cell and baseloid SCC, but these have not been associated 
with specific gene signatures and therefore are only 
important in diagnostics.
The incidence of SCC has dropped in the last three 
decades from a major entity representing 35% of lung 
carcinomas to around 17%. One of the major reasons 
is the shift from filter-less to filter cigarettes. This has 
resulted in the reduction of particle-bound carcinogens 
and increase of vaporized carcinogens, which more easily 
reach the bronchioloalveolar terminal unit, inducing mainly 
adenocarcinomas.
In the past, SCC was mainly a diagnosis required 
to exclude several therapeutic options in the clinic: 
no pemetrexed therapy, no antiangiogenic drugs, less 
responsiveness to cisplatin treatment. However, this has 
changed within the last 3 years, as there are several emerging 
new targets for treatment of SCC.
Fibroblast growth factor receptor 1 (FGFR1)
FGFR1 was identified being amplified in about 20% of 
SCCs (53) [M. Sharp et al., Poster presentation, American 
Association for Cancer Research (AACR) meeting 2011]. 
In experimental studies as well as in ongoing clinical trials 
it was found that only amplification, proven by in-situ 
hybridization methods identified patients, who respond 
to small molecule inhibitor treatment (54). In subsequent 
trials the FGFR1-TKI therapy failed despite amplification: 
it became clear recently that there are additional genetic 
changes in some of these patients, specifically CA-PI3K 
mutations or amplifications. So in future the tumor in these 
patients will require analysis for several genes.
Discoidin domain receptor tyrosine kinase 2 (DDR2) 
and FGFR2
DDR2 and FGFR2 mutations are found exclusively in 
SCCs, however, only in a small percentage, 4% and 2%, 
respectively (55). In DDR2 mutated SCC patients some 
TKIs were successfully applied (56,57). For FGFR2 
multikinase inhibitors might be an option for specific 
treatment (58,59).
Large cell carcinoma (LCC)
LCC is defined by large cells (nuclei >25 µm) devoid of 
any cytoplasmic differentiation, and large vesicular nuclei. 
They have a well-ordered solid structure. By electron 
microscopy differentiation structures can be seen such 
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as hemidesmosomes, tight junctions, intracytoplasmic 
vacuoles with microvilli, and ill-formed cilia. This fits 
clearly into the concept of a carcinoma, at the doorstep of 
adenocarcinoma and SCC differentiation. LCC numbers 
have dramatically decreased due to the routine use of 
immunohistochemistry for more precise sub-classification of 
NSCLC. Using TTF1, low-molecular cytokeratins, as well 
as p63 and cytokeratin 5/6 most cases of LCC were either 
reclassified into adenocarcinoma or SCC, respectively (60). 
These recent changes make an evaluation of genetic 
aberrations in LCC quite difficult, since genetic studies 
were based on previous classifications.
Not surprisingly EGFR mutations, MET amplifications, 
and  EML4ALK1 fus ions  have  been  repor ted  in 
LCC (61). LKB1, a gene mutated in a small percentage of 
adenocarcinomas was also shown in squamous and large 
cell carcinomas (62). LKB1, also known as serine/threonine 
kinase 11 (STK11), is involved in the negative regulation 
of mechanistic target of rapamycin (mTOR) and closely 
cooperates with tuberous sclerosis gene (TSC) 1 and 2 
genes (63).  
Resistance mechanisms
There are general classes of resistance mechanisms to TKI 
therapy. The target can be altered by a secondary inhibitory 
mutation or by amplification. The second class is a bypass 
track, by which the blocked TK is circumvented. Finally 
the tumor may undergo phenotypic and genotypic changes, 
which makes TKI-therapy inefficient.
The most frequent resistance mechanisms for EGFR 
are inhibitory mutations on exons 20 and 19. The most 
common ones on exon 20 are D770_N771 insertions (up 
to 3%) and the mutations T790M, V769L, N771T, and 
the D761Y mutation on exon 19 (64-66). Several of these 
mutations might be targeted by second and third generation 
TKIs (67). A common bypass track in EGFR mutated 
adenocarcinomas is amplification of the MET receptor 
(64,68,69). A third mechanism is a phenotypic change of 
the tumor. A transition from adenocarcinoma to small cell 
carcinoma has been reported. Also re-biopsies have shown 
a transition from a well-differentiated adenocarcinoma to 
an undifferentiated carcinoma (57,70-72). Concomitant 
to this phenotypic change also genotypic changes are 
seen: a SCLC no longer presents with EGFR mutation 
but will respond to classical chemotherapy. In transgenic 
mice an upregulation of pS6 might explain some of these 
phenomena. Two new resistance mechanisms have been 
reported on a recent poster session: methylation of PTEN 
promoter region caused a deactivation of PTEN (similar 
to PTEN loss) and subsequent upregulation of PI3K-AKT 
pathway. The second resistance mechanism was an aberrant 
signaling of EGFR into SRC kinases, thus circumventing 
the effect of EGFR blockade by TKI (Izumi et al., ERS 
Congress Munich, Sep. 6th, 2014).
Resistance mechanisms in EML4ALK rearranged lung 
adenocarcinomas do exist, however, the exact mechanisms 
are still under investigation (73,74). Most common are 
secondary mutations in the ALK domain. Most common 
are L1196M and G1269A, less common are 1151Tins, 
L1152R, C1156Y, F1174L, G1202R, and S1206Y (75-77). 
Again bypass mechanisms do occur such as MET activation, 
but also ALK amplification. Interestingly second and third 
generation ALK inhibitors can target most of the secondary 
mutations. However, also these new generation ALK 
inhibitors will induce secondary resistance mutations, for 
which new drugs have to be designed (78,79).
Similar to EGFR and EML4ALK also for ROS1, KIF5B, 
and RET secondary mutations have been reported (80,81). 
For MET this can be expected, but so far treatment has just 
started with MET inhibitors.
Resistance mechanisms for FGFR1 inhibition are still not 
exactly known. The major problem in this setting of SCCs is 
complicated, because response to treatment might be dictated 
by the mode of FGFR1 modification in the carcinoma: 
mutation, amplification, deletion, and/or multiple alterations. 
In lung SCCs the prevalent alterations are amplification and 
mutation (53,82). This has largely been ignored, therefore 
the outcome and response has to be reevaluated. Using TKIs 
for FGFR1 some carcinomas responded quite well, whereas 
others not. Another problem in FGFR1 amplified pulmonary 
SCCs is the coincidence of FGFR1 amplification with PI3K 
mutations and amplifications (82). These new findings have 
to taken into account, before resistance mechanisms can be 
further explored.
Treatment for DDR2 and FGFR2 mutations has been 
applied in few patients. A resistance mutation has already 
been shown in cell culture studies using cell lines with 
DDR2 mutation (83). So far this has not been seen in 
patients.
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